← Back to Screener
Lantern Pharma Inc. Common Stock (LTRN)
Price$3.74
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)3.74%
Price vs S&P 500 (4W)64.37%
VGM Score65.81
Market Capitalization$40.58M
All Metrics
Book Value / Share (Quarterly)$0.31
P/TBV (Annual)0.78x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.34
Price vs S&P 500 (YTD)7.55%
EPS (TTM)$-1.45
10-Day Avg Trading Volume0.29M
EPS Excl Extra (TTM)$-1.45
EPS (Annual)$-1.57
ROI (Annual)-262.00%
Cash / Share (Quarterly)$0.56
ROA (Last FY)-155.13%
EBITD / Share (TTM)$-1.51
ROE (5Y Avg)-88.36%
Cash Flow / Share (Annual)$-1.39
P/B Ratio11.78x
P/B Ratio (Quarterly)4.47x
Net Income / Employee (Annual)$-1,070,000
ROA (TTM)-129.09%
EPS Incl Extra (Annual)$-1.57
Current Ratio (Annual)2.40x
Quick Ratio (Quarterly)1.67x
3-Month Avg Trading Volume0.48M
52-Week Price Return14.70%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.18
52-Week High$5.74
EPS Excl Extra (Annual)$-1.57
CapEx CAGR (5Y)-38.78%
26-Week Price Return19.67%
Quick Ratio (Annual)2.25x
13-Week Price Return26.41%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.87x
Enterprise Value$35.67M
Book Value / Share Growth (5Y)-28.77%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.90
3-Month Return Std Dev142.26%
Net Income / Employee (TTM)$-994,500
ROE (Last FY)-262.00%
EPS Basic Excl Extra (Annual)$-1.57
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.45
ROI (TTM)-198.35%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.16
Price vs S&P 500 (52W)-13.51%
Year-to-Date Return18.48%
5-Day Price Return2.57%
EPS Normalized (Annual)$-1.57
ROA (5Y Avg)-62.78%
Month-to-Date Return75.12%
Cash Flow / Share (TTM)$-1.39
EBITD / Share (Annual)$-1.65
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-88.36%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.45
P/TBV (Quarterly)0.97x
P/B Ratio (Annual)5.19x
Book Value / Share (Annual)$0.58
Price vs S&P 500 (13W)16.66%
Beta2.34x
Revenue / Share (TTM)$0.00
ROE (TTM)-198.35%
52-Week Low$1.11
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.30est. -0.37
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LTRNLantern Pharma Inc. Common Stock | — | — | B | $3.74 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Lantern Pharma uses artificial intelligence to accelerate oncology drug discovery and development. The company's proprietary RADR platform applies machine learning to oncology-focused data, reducing drug development costs and timelines. Its growing pipeline of precision cancer therapies is powered by AI-driven insights and partnerships with leading scientific experts.